159 / 1498
non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the
International, Randomized, Phase III First-Line Indolent trial.
Morschhauser F, et al J Clin Oncol. 2013 ;31(16):1977-83.
90
Y-ibritumomab: n = 107
Median PFS: > 107 mo
Control: n = 108
Median PFS: 32.4 mo
0
25
50
75
100
Cumulative Percentage
The 7-year PFS among patients with a CR/CRu after induction was
36% in the control arm compared with 57% in the
90
Y-ibritumomab arm
HR = 1.72 (95% CI: 1.18 – 2.50);
P
= 0.004
90
Y-ibritumomab
Control
107
108
47
67
N F
PFS From Time of Randomization (months)
90
Y-ibritumomab
Control
107
79
65
60
49
53
39
16
11
At risk:
108
0
21
42
63
84